Zobrazeno 1 - 10
of 66
pro vyhledávání: '"Hamim, Zahir"'
Autor:
Xavier J. H. Pepin, Scott M. Hynes, Hamim Zahir, Deborah Walker, Lois Q. Semmens, Sandra Suarez‐Sharp
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 13, Iss 10, Pp 1771-1783 (2024)
Abstract Omaveloxolone is a nuclear factor (erythroid‐derived 2)‐like 2 activator approved in the United States and the European Union for the treatment of patients with Friedreich ataxia aged ≥16 years, with a recommended dosage of 150 mg oral
Externí odkaz:
https://doaj.org/article/d460f6850b8b4da5a5d2f5e21b780d1f
Autor:
Sonomi Maruyama, Hester Visser, Takashi Ito, Tharin Limsakun, Hamim Zahir, Daniel Ford, Ben Tao, Cynthia A. Zamora, Jeffrey G. Stark, Hubert S. Chou
Publikováno v:
Clinical and Translational Science, Vol 15, Iss 4, Pp 967-980 (2022)
Abstract Tissue‐nonspecific alkaline phosphatase (TNAP) hydrolyzes and inactivates inorganic pyrophosphate (PPi), a potent inhibitor of calcification; therefore, TNAP inhibition is a potential target to treat ectopic calcification. These two first
Externí odkaz:
https://doaj.org/article/9aae7b03315b4d68a312748a6d368b03
Autor:
Ophelia Yin, Hamim Zahir, Jonathan French, Daniel Polhamus, Xiaoning Wang, Michiel van deSande, William D. Tap, Hans Gelderblom, Andrew J. Wagner, John H. Healey, Jonathan Greenberg, Dale Shuster, Silvia Stacchiotti
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 11, Pp 1422-1432 (2021)
Abstract This analysis was conducted to assess exposure–response relationships for efficacy and safety of pexidartinib in patients with tenosynovial giant cell tumor. Efficacy was assessed categorically by overall response rate (ORR) with Response
Externí odkaz:
https://doaj.org/article/e98d8752c9444f7c9cdac6701994c7d3
Autor:
Hamim Zahir, Ophelia Yin, Ching Hsu, Andrew J. Wagner, Jason Jiang, Xiaoning Wang, Jon Greenberg, Dale E. Shuster, Tarundeep Kakkar, Frank LaCreta
Publikováno v:
Clinical Pharmacology in Drug Development. 12:475-483
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2dce8edef52258022515ff6e4c3c2aaa
https://doi.org/10.1002/cpdd.1240
https://doi.org/10.1002/cpdd.1240
Autor:
Jeanne Mendell, Naama Levy-Cooperman, Ed Sellers, Bradley Vince, Debra Kelsh, James Lee, Vance Warren, Hamim Zahir
Publikováno v:
Therapeutic Advances in Drug Safety, Vol 10 (2019)
Mirogabalin is a selective calcium channel α 2 δ subunit ligand being developed to treat neuropathic pain. In accordance with US Food and Drug Administration (FDA) guidance, the human abuse potential of mirogabalin (15–105 mg) was examined, relat
Externí odkaz:
https://doaj.org/article/37456564e4f841f183fcf30f1159c575
Autor:
Hamim Zahir, Jonathan Greenberg, Ching Hsu, Thomas C. Marbury, Kenneth C. Lasseter, Li‐An Xu, William D. Tap, John H. Healey, Silvia Stacchiotti, Frank LaCreta
Publikováno v:
The Journal of Clinical Pharmacology. 62:992-1005
Pexidartinib is a novel oral small-molecule tyrosine kinase inhibitor targeting the colony-stimulating factor 1 receptor. Pexidartinib undergoes extensive hepatic metabolism via multiple cytochrome P450 and uridine 5'-diphospho-glucuronosyl transfera
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49d00de353ab2e8e64d97709fe255066
https://doi.org/10.1002/jcph.2042
https://doi.org/10.1002/jcph.2042
Autor:
Daigo Asano, Syoya Hamaue, Hamim Zahir, Hideyuki Shiozawa, Yumi Nishiya, Takako Kimura, Miho Kazui, Naotoshi Yamamura, Marie Ikeguchi, Takahiro Shibayama, Shin-ichi Inoue, Tsuyoshi Shinozuka, Toshiyuki Watanabe, Chizuko Yahara, Nobuaki Watanabe, Kouichi Yoshinari
Publikováno v:
Drug Metabolism and Disposition. 50:235-242
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::70186cea69d28e89cf0b2a4873bd0d31
https://doi.org/10.1124/dmd.121.000665
https://doi.org/10.1124/dmd.121.000665
Publikováno v:
Clinical pharmacokinetics. 61(11)
Pexidartinib is a novel oral small-molecule inhibitor that selectively targets colony-stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3 harboring an internal tandem duplication mutation. It is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::555c62de40dc45bc6b513d7b5396d0c5
https://pubmed.ncbi.nlm.nih.gov/36264536
https://pubmed.ncbi.nlm.nih.gov/36264536
Autor:
Michael S. Gordon, Andrew J. Wagner, Fumiaki Kobayashi, Hamim Zahir, Cynthia Zamora, Roohi Gajee, Jonathan Greenberg, Qiang Wang, Hani M. Babiker
Publikováno v:
Journal of Clinical Pharmacology
Pexidartinib is approved for treatment of adults with symptomatic tenosynovial giant cell tumor. In vitro data showed pexidartinib's potential to inhibit and induce cytochrome P450 (CYP) 3A, inhibit CYP2C9, CYP2C19 and P‐glycoprotein (P‐gp). Here
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::955ef7d956c23011d0f30d246a5ea56a
https://doi.org/10.1002/jcph.1734
https://doi.org/10.1002/jcph.1734
Autor:
Dale Shuster, Hans Gelderblom, Hamim Zahir, Michiel A. J. van de Sande, William D. Tap, Daniel Polhamus, Jonathan French, John H. Healey, Silvia Stacchiotti, Ophelia Yin, Jonathan Greenberg, Xiaoning Wang, Andrew J. Wagner
Publikováno v:
CPT: Pharmacometrics and Systems Pharmacology, 10(11), 1422-1432. WILEY
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 11, Pp 1422-1432 (2021)
CPT: Pharmacometrics & Systems Pharmacology
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 11, Pp 1422-1432 (2021)
CPT: Pharmacometrics & Systems Pharmacology
This analysis was conducted to assess exposure–response relationships for efficacy and safety of pexidartinib in patients with tenosynovial giant cell tumor. Efficacy was assessed categorically by overall response rate (ORR) with Response Evaluatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6fde6cee7310aa36880d826b65e2155e
https://hdl.handle.net/1887/3274139
https://hdl.handle.net/1887/3274139
